S11 E05: Pharma's year in review 2025

This week, Isabel brings together three expert voices for an end-of-year round-up, reflecting on the moments that shaped healthcare and life sciences in 2025. Joined by Jonathan Sackier, Chairman, Medical Advisory Board, EMJ, Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, and omnichannel expert Yacin Marzouki, the conversation looks back on a year defined by both disruption and progress.

Across the episode, the contributors share their perspectives on the biggest setbacks and standout successes of the past 12 months, from regulatory uncertainty and access challenges to collaboration, innovation and scientific momentum. They also reflect on the lessons 2025 has taught them, and what those insights mean for patients, industry and the year ahead.

Hanna Svanbäck

Executive Director for Neuroscience, Eli Lilly

With over 15 years at Eli Lilly, Hanna leads Neuroscience operations across the UK, Ireland and the Nordics, driving scientific innovation and patient-centred research.

Jonathan Sackier

Chairman, Medical Advisory Board, EMJ

Jonathan is a surgeon by training and a founding partner of many start-ups in the medical technology space, as well as being the creator of the world's first operating room robot.

Yacin Marzouki

Omnichannel expert

Within the pharmaceutical sector, Yacin specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution.